Evidence map›Paper›PMID 30249495›Full record

ArticleBioorganic & medicinal chemistry2018

Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study.

Rita Fuerst, Jun Yong Choi, Anna M Knapinska, Lyndsay Smith, Michael D Cameron, Claudia Ruiz, Gregg B Fields, William R Roush

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Pyrazolo[4,3-ACS medicinal chemistry letters · 2020
    Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rita FuerstDepartment of Chemistry, Scripps Florida, Jupiter, FL 33458, United States; Institute of Organic Chemistry, Graz University of Technology, 8010 Graz, Austria.
Jun Yong ChoiDepartment of Chemistry, Scripps Florida, Jupiter, FL 33458, United States; Department of Chemistry and Biochemistry, Queens College and the Graduate Center of the City University of New York, New York 11367, United States.
Anna M KnapinskaDepartment of Chemistry & Biochemistry, Florida Atlantic University, Jupiter, FL 33458, United States.
Lyndsay SmithDepartment of Chemistry & Biochemistry, Florida Atlantic University, Jupiter, FL 33458, United States.
Michael D CameronDepartment of Chemistry, Scripps Florida, Jupiter, FL 33458, United States.
Claudia RuizDepartment of Chemistry, Scripps Florida, Jupiter, FL 33458, United States.
Gregg B FieldsDepartment of Chemistry & Biochemistry, Florida Atlantic University, Jupiter, FL 33458, United States.
William R RoushDepartment of Chemistry, Scripps Florida, Jupiter, FL 33458, United States. Electronic address: roush@scripps.edu.

Funding

New probes for matrix metalloproteinase 13R01AR063795 · NIAMS · TORREY PINES INST FOR MOLECULAR STUDIES · PI FIELDS, GREGG B · 2013 to 2015
$1.5M
Austrian Science Fund FWF J 3567NIAMS NIH HHS R01 AR063795
6 · The paper itself

Abstract

A structure-activity/structure-property relationship study based on the physicochemical as well as in vitro pharmacokinetic properties of a first generation matrix metalloproteinase (MMP)-13 inhibitor (2) was undertaken. After systematic variation of inhibitor 2, compound 31 was identified which exhibited microsomal half-life higher than 20 min, kinetic solubility higher than 20 μM, and a permeability coefficient greater than 20 × 10

Indexed as

AnimalsCytochrome P-450 Enzyme InhibitorsHalf-LifeHumansInhibitory Concentration 50KineticsMatrix Metalloproteinase 13Matrix Metalloproteinase InhibitorsMiceMicrosomes, LiverModels, AnimalRatsSolubilityStructure-Activity RelationshipCytochrome P-450 Enzyme InhibitorsMatrix Metalloproteinase 13Matrix Metalloproteinase InhibitorsIn vitro and in vivo pharmacokineticsMatrix metalloproteinase 13Microsomal stabilityPermeabilitySolubilityStructure-activity relationshipStructure-property relationship

Identifiers

PMID30249495
PMCPMC6379921

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.